Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
Indianapolis-based Eli Lilly and Co. has joined two other companies to contribute $40 million to an early-stage life sciences venture capital initiative in New York City.
With a $60 million-plus investment, the university aims to take molecules from discovery to clinical trials.
Retiring Indiana University School of Medicine Dean Dr. Craig Brater has, in his 13-year tenure, doubled the school’s number of research-oriented faculty to 700, doubled the amount of space for them to work in, and doubled the revenue from research grants and contracts. But all that effort has hardly budged IU in national rankings.
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a “world-class” research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
Purdue University’s Regenstrief Center for Healthcare Engineering will get another $10 million from the Indianapolis-based Regenstrief Foundation, keeping its research going through 2018.
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
The university says the gift from an alumnus will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, in hopes of accelerating discovery of new treatments for heart disease, diabetes and some cancers.